shire map
Select a

Shire Global


United States Product Patent Information

In accordance with 35 USC § 287(a), Baxalta Incorporated provides United States Patent information concerning its products on this website. For each of the products listed below, the product is patented under, made under, or used under one or more of the patents listed with the product name.

The patent information displayed on this page is believed to be accurate as of the most recent update of the page, but should not be considered exhaustive. In particular, the omission of a particular patent from a product’s entry on this page is not a representation or admission by Baxalta that that patent does not cover the product; nor does the absence of any listing on this page for a specific Baxalta product constitute a representation or admission by Baxalta that that product is unpatented. In addition, although Baxalta has attempted to keep the information on this page reasonably current, certain patents listed on this page may still have expired since the page was last updated.

Please note that prior to July 1, 2015, some of the products marketed below were sold by Baxter International Inc. through its subsidiaries. These products may be marketed currently by Baxalta with labeling that references a subsidiary of Baxter International Incorporated as the manufacturer and/or distributor, and that reference the Baxter International Incorporated patent-marking webpage,

Please find the product name below to view associated United States Patents.

ADVATE (antihemophilic factor [recombinant]) lyophilized powder for reconstitution) and BAXJECT III

  • Patented under U.S. Patent Numbers: 5,733,873; 5,854,021; 5,919,766; 5,955,448; 6,313,102; 6,586,573; 6,649,386; 7,087,723 and 7,247,707, 8,545,476. Made according to the method of U.S.

Patent Numbers: 6,100,061; 6,475,725; 6,555,391; 6,936,441; 7,094,574; 7,253,262 and 7,381,796.

HYQVIA [Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase

  • Patented under U.S. Patent Number 7,767,429, under license from Halozyme, Inc., a wholly owned subsidiary of Halozyme Therapeutics, Inc. 

Cookie Use Notification

The site uses cookies to provide you with a more responsive and personalized service. By using this site you agree to our use of cookies as set out in our cookie notice. Please read our privacy notice for more information on the cookies we use and how to delete or block the use of cookies. LEARN MORE